undamentalytics Newsletter
Sign in

Kura Oncology, Inc. balance sheet

At the end of fiscal 2025, Kura Oncology, Inc. had total assets of $738m, total liabilities of $564m and shareholders' equity of $174m. It held $149m in cash against $9.7m of debt: net cash of $139m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents3722414970
Receivables—299
Inventory—002
Total current assets432745709559
Total assets449760738588
Accounts payable2152
Deferred revenue (current)—244955
Total current liabilities3579117118
Short-term debt—304
Long-term debt97106
Total debt9101010
Total liabilities52347564539
Shareholders' equity39741417448
Net debt (negative = net cash)−28−215−139−60
Shares outstanding74m78m88m89m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ADCT vs KURAASMB vs KURAAAPG vs KURA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kura Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kura Oncology, Inc.